BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

526 related articles for article (PubMed ID: 2557876)

  • 1. Comparisons in vitro, ex vivo, and in vivo of the actions of seven structurally diverse inhibitors of angiotensin converting enzyme (ACE).
    Cushman DW; Wang FL; Fung WC; Grover GJ; Harvey CM; Scalese RJ; Mitch SL; DeForrest JM
    Br J Clin Pharmacol; 1989; 28 Suppl 2(Suppl 2):115S-130S; discussion 130S-131S. PubMed ID: 2557876
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Differentiation of angiotensin-converting enzyme (ACE) inhibitors by their selective inhibition of ACE in physiologically important target organs.
    Cushman DW; Wang FL; Fung WC; Harvey CM; DeForrest JM
    Am J Hypertens; 1989 Apr; 2(4):294-306. PubMed ID: 2706094
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Effects of different angiotensin-converting enzyme (ACE) inhibitors on ischemic isolated rat hearts: relationship between cardiac ACE inhibition and cardioprotection.
    Grover GJ; Sleph PG; Dzwonczyk S; Wang P; Fung W; Tobias D; Cushman DW
    J Pharmacol Exp Ther; 1991 Jun; 257(3):919-29. PubMed ID: 1646329
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Angiotensin converting enzyme inhibition in heart, kidney, and serum studied ex vivo after administration of zofenopril, captopril, and lisinopril.
    Sun Y; Mendelsohn FA
    J Cardiovasc Pharmacol; 1991 Oct; 18(4):478-86. PubMed ID: 1724523
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Fosinopril and zofenopril, two angiotensin-converting enzyme (ACE) inhibitors, potentiate the anticonvulsant activity of antiepileptic drugs against audiogenic seizures in DBA/2 mice.
    Sarro GD; Paola ED; Gratteri S; Gareri P; Rispoli V; Siniscalchi A; Tripepi G; Gallelli L; Citraro R; Russo E
    Pharmacol Res; 2012 Mar; 65(3):285-96. PubMed ID: 22107891
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Regression of ventricular and vascular hypertrophy: are there differences between structurally different angiotensin-converting enzyme inhibitors?
    Raasch W; Bartels T; Schwartz C; Häuser W; Rütten H; Dominiak P
    J Hypertens; 2002 Dec; 20(12):2495-504. PubMed ID: 12473875
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Competitive inhibition of glycylsarcosine transport by enalapril in rabbit renal brush border membrane vesicles: interaction of ACE inhibitors with high-affinity H+/peptide symporter.
    Lin CJ; Akarawut W; Smith DE
    Pharm Res; 1999 May; 16(5):609-15. PubMed ID: 10350000
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Fosinopril, a phosphinic acid inhibitor of angiotensin I converting enzyme: in vitro and preclinical in vivo pharmacology.
    DeForrest JM; Waldron TL; Harvey C; Scalese B; Rubin B; Powell JR; Petrillo EW; Cushman DW
    J Cardiovasc Pharmacol; 1989 Nov; 14(5):730-6. PubMed ID: 2481187
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Attenuation of myocardial reperfusion injury by sulfhydryl-containing angiotensin converting enzyme inhibitors.
    Liu X; Engelman RM; Rousou JA; Cordis GA; Das DK
    Cardiovasc Drugs Ther; 1992 Aug; 6(4):437-43. PubMed ID: 1387799
    [TBL] [Abstract][Full Text] [Related]  

  • 10. ACE inhibition and protection from doxorubicin-induced cardiotoxicity in the rat.
    Sacco G; Mario B; Lopez G; Evangelista S; Manzini S; Maggi CA
    Vascul Pharmacol; 2009; 50(5-6):166-70. PubMed ID: 19344651
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Mitigation of experimental radiation nephropathy by renin-equivalent doses of angiotensin converting enzyme inhibitors.
    Moulder JE; Cohen EP; Fish BL
    Int J Radiat Biol; 2014 Sep; 90(9):762-8. PubMed ID: 24991882
    [TBL] [Abstract][Full Text] [Related]  

  • 12. [Angiotensin converting enzyme inhibitory activity of MK-0521 in vivo and antihypertensive effect of its single oral administration on blood pressure and effect on the renin-angiotensin system in 2-kidney Goldblatt hypertensive dogs].
    Oda M; Ino Y; Suzuki K; Sato T; Iwamoto S; Iwaki M
    Nihon Yakurigaku Zasshi; 1989 Apr; 93(4):225-34. PubMed ID: 2545579
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Clinical pharmacokinetics and selective pharmacodynamics of new angiotensin converting enzyme inhibitors: an update.
    Song JC; White CM
    Clin Pharmacokinet; 2002; 41(3):207-24. PubMed ID: 11929321
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Antihypertensive action of the converting enzyme inhibitor perindopril (S9490-3) in spontaneously hypertensive rats: comparison with enalapril (MK421) and ramipril (Hoe498).
    Unger T; Moursi M; Ganten D; Hermann K; Lang RE
    J Cardiovasc Pharmacol; 1986; 8(2):276-85. PubMed ID: 2422465
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Differential antiplatelet effects of angiotensin converting enzyme inhibitors: comparison of ex vivo platelet aggregation in cardiovascular patients with ramipril, captopril and enalapril.
    Skowasch D; Viktor A; Schneider-Schmitt M; Lüderitz B; Nickenig G; Bauriedel G
    Clin Res Cardiol; 2006 Apr; 95(4):212-6. PubMed ID: 16598590
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Preclinical pharmacology of zofenopril, an inhibitor of angiotensin I converting enzyme.
    DeForrest JM; Waldron TL; Krapcho J; Turk C; Rubin B; Powell JR; Cushman DW; Petrillo EW
    J Cardiovasc Pharmacol; 1989 Jun; 13(6):887-94. PubMed ID: 2484083
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Comparison of the steady-state pharmacokinetics of fosinopril, lisinopril and enalapril in patients with chronic renal insufficiency.
    Sica DA; Cutler RE; Parmer RJ; Ford NF
    Clin Pharmacokinet; 1991 May; 20(5):420-7. PubMed ID: 1652404
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Physicochemical and enzyme binding kinetic properties of a new angiotensin-converting enzyme inhibitor ramipril and their clinical implications.
    Bender N; Rangoonwala B; Rosenthal J; Vasmant D
    Clin Physiol Biochem; 1990; 8 Suppl 1():44-52. PubMed ID: 2147879
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Relative lipophilicities and structural-pharmacological considerations of various angiotensin-converting enzyme (ACE) inhibitors.
    Ranadive SA; Chen AX; Serajuddin AT
    Pharm Res; 1992 Nov; 9(11):1480-6. PubMed ID: 1475237
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Antihypertensive activity during inhibition of neutral endopeptidase and angiotensin converting enzyme.
    Seymour AA; Swerdel JN; Abboa-Offei B
    J Cardiovasc Pharmacol; 1991 Mar; 17(3):456-65. PubMed ID: 1711608
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 27.